Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 2/20 | 0.45 |
| ▸ | TACR1 | P25103 | 3/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.45 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.45 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 3/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22713230 | 1.00 | SCN4A (0.45) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL20491536 | 0.80 | IDO1 (0.40) | DPP4GBA1 | |
| SCHEMBL12261606 | 0.80 | TACR1 (0.47) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL12574579 | 0.80 | TACR1 (0.47) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| Hydrochloric Acid SCHEMBL22229344 | 0.78 | TACR1 (0.46) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL9057427 | 0.78 | HTR2A (0.46) | CACNA1FCACNA1DCACNA1SCACNA1CDPP4 | |
| SCHEMBL5461547 | 0.77 | SCN4A (0.45) | SCN4ADPP4F2GBA1 | |
| SCHEMBL15165328 | 0.77 | SCN4A (0.45) | SCN4ADPP4F2GBA1 | |
| SCHEMBL16291590 | 0.77 | SCN4A (0.45) | SCN4ADPP4F2GBA1 | |
| SCHEMBL23241788 | 0.77 | TACR1 (0.37) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486281-B2 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| US-12448359-B2 | Compounds with immunomodulatory activity and therapeutic uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2025-10-21 | — | — | US | disclosed |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| EP-4288412-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | Rappta Therapeutics Oy (FI) | 2023-12-13 | — | — | EP | disclosed |
| EP-3816158-B1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS IDH1 INHIBITORS | KPC PHARMACEUTICALS INC (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-20230159475-A1 | COMPOUNDS WITH IMMUNOMODULATORY ACTIVITY AND THERAPEUTIC USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2023-05-25 | — | — | US | disclosed |
| US-20120238607-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| US-8202895-B2 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-19 | — | — | US | disclosed |
| EP-2408751-A1 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | Bayer Pharma Aktiengesellschaft (DE) | 2012-01-25 | — | — | EP | disclosed |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| WO-2010105770-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-23 | — | — | WO | disclosed |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
| WO-2008130581-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-0922050-B1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2003-07-30 | — | — | EP | disclosed |
| CN-1224426-A | 3-descladinose-2, 3-anhydroerythromycin derivatives | ABBOTT LAB (US) | 1999-07-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | SCN4A 2259/4885TACR1 2933/4885CACNA1F 3128/4885 |
| US-20120238607-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | AADAC, NAT1, TNNT2 | SCN4A 1100/4885TACR1 4116/4885CACNA1F 1033/4885 |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GPR65 | SCN4A 4282/4885TACR1 104/4885CACNA1F 3661/4885 |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPM1A, PPP2CA, PPP3CA | SCN4A 2302/4885TACR1 4078/4885CACNA1F 2910/4885 |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | SCN4A 2263/4885TACR1 2939/4885CACNA1F 3144/4885 |
| US-20230159475-A1 | COMPOUNDS WITH IMMUNOMODULATORY ACTIVITY AND THERAPEUTIC USES THEREOF | CD47, CD74, ICOS | SCN4A 4781/4885TACR1 2556/4885CACNA1F 4874/4885 |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | AADAC, NAT1, TNNT2 | SCN4A 1100/4885TACR1 4116/4885CACNA1F 1033/4885 |
| US-12448359-B2 | Compounds with immunomodulatory activity and therapeutic uses thereof | CD47, CD74, ICOS | SCN4A 4781/4885TACR1 2556/4885CACNA1F 4874/4885 |
| US-12486281-B2 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | CPT1A, GOT2, IDH2 | SCN4A 566/4885TACR1 3786/4885CACNA1F 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.